Dr. Schachter specializes in ocular surface disease and serves as a Vision Source administrator for central California coast. He serves on the advisory board for Allergan, BlephEx, Sun Pharma, and ScienceBased Health, and he is a speaker for Allergan, Bau
There is treatment hope for neurotrophic keratitis, a rare disease affecting the cornea.
Scott Schachter, OD, reviews Oxervate, the first FDA-approved treatment for neurotrophic keratitis to exhibit complete corneal healing.
